AstraZeneca PLC is in advanced talks to pay more than $5 billion for little-known biotech company Acerta Pharma BV and its promising cancer compound, according to people familiar with the matter, in the U.K. drugmaker's latest effort to rebuild its pipeline. The companies aim to announce a deal this month, some of the people said, but there is no guarantee an agreement will be reached.